Lineage Cell Therapeutics, Inc. Common Stock · Total Non-Current Liabilities

Latest reported$57.87Mperiod endingDec 31, 2025

LCTX FY Total Non-Current Liabilities ($200.00K → $57.87M)

Annual total non-current liabilities

High-resolution chart · PNG

LCTX total non-current liabilities history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Lineage Cell Therapeutics, Inc. Common Stock Total Non-Current Liabilities — Annual fiscal periods (USD)
Period ending	Total Non-Current Liabilities (USD)
Dec 31, 2025	57,871,000
Dec 31, 2024	22,229,000
Dec 31, 2023	21,036,000
Dec 31, 2022	32,747,000
Dec 31, 2021	36,531,000
Dec 31, 2020	5,053,000
Dec 31, 2019	7,737,000
Dec 31, 2018	2,602,000
Dec 31, 2017	2,099,000
Dec 31, 2016	3,214,000
Dec 31, 2015	5,751,000
Dec 31, 2014	5,048,874
Dec 31, 2013	8,509,529
Dec 31, 2012	1,063,388
Dec 31, 2011	1,224,859
Dec 31, 2010	1,367,045
Dec 31, 2009	1,223,823
Dec 31, 2008	2,003,754
Dec 31, 2007	1,763,489
Dec 31, 2006	1,900,080
Dec 31, 2005	1,448,768
Dec 31, 2004	901,563
Dec 31, 2003	407,813
Dec 31, 2002	2,168,804
Dec 31, 2001	1,731,122
Dec 31, 2000	359,749
Dec 31, 1999	595,512
Dec 31, 1998	200,000
Jun 30, 1998	200,000
Jun 30, 1996	100,000
Jun 30, 1995	100,000
Jun 30, 1994	100,000
Jun 30, 1993	100,000
Jun 30, 1992	200,000